RAPT Therapeutics, Inc. (RAPT) Operating Leases (2022 - 2024)
RAPT Therapeutics (RAPT) has disclosed Operating Leases for 3 consecutive years, with $2.6 million as the latest value for Q3 2024.
- Quarterly Operating Leases fell 48.8% to $2.6 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Sep 2024, down 48.8% year-over-year, with the annual reading at $4.5 million for FY2023, 34.62% down from the prior year.
- Operating Leases hit $2.6 million in Q3 2024 for RAPT Therapeutics, down from $3.2 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $7.1 million in Q1 2022 to a low of $2.6 million in Q3 2024.
- Historically, Operating Leases has averaged $5.3 million across 3 years, with a median of $5.7 million in 2023.
- Biggest five-year swings in Operating Leases: dropped 12.15% in 2023 and later crashed 48.8% in 2024.
- Year by year, Operating Leases stood at $6.8 million in 2022, then tumbled by 34.62% to $4.5 million in 2023, then plummeted by 41.75% to $2.6 million in 2024.
- Business Quant data shows Operating Leases for RAPT at $2.6 million in Q3 2024, $3.2 million in Q2 2024, and $3.8 million in Q1 2024.